Novartis CEO eyes growth strategies for Alcon

Novartis ($NVS) CEO Joe Jimenez (photo) told Reuters in an interview about his plans for the company's new eye-care division Alcon, which include broader use of implanted lenses and a larger presence in emerging markets. Report

Suggested Articles

Several of the industry's top players had a strong performance in the fourth quarter, growing revenues at high single digits. Others? Not so much.

Viatris, the merger of Mylan and Pfizer's Upjohn, has fleshed out its board and C-suite with a raft of Pfizer and Mylan veterans.

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.